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IndiaIn this issue of Indian Heart Journal, the Dyslipidemia Residual
and Mixed Abnormalities IN spite of Statin therapy (REMAINS)
Study is published.1 This is a prospective, multicenter,
observational cohort study that investigated changes in lipid
parameters between baseline (pre-statin therapy) and after
statin therapy or other lipid lowering treatments amongst
adult patients hospitalized for their ﬁrst acute coronary
syndrome (ACS).1 REMAINS included 474 patients who
were treated with various doses of a statin, mainly high
dose atorvastatin, during their hospitalization for an ACS.1 The
primary outcome was changes in lipid proﬁle during the
12-week period until the end of study (EOS).1 Comparisons
between baseline lipid values and those at the EOS showed
that low-density lipoprotein cholesterol (LDL-C) levels were
controlled at a satisfactory degree, while high-density lipo-
protein cholesterol (HDL-C) levels decreased and there were no
major difference in the levels of TG (baseline TG levels were
high, either alone or along with other lipid levels).1 Thus, the
conclusions of the REMAINS study were that though statin
therapy is effective in lowering LDL-C, according to current
guidelines and standards of care, in patients with atherogenic
dyslipidemia (AD), residual dyslipidemia still remains; this
should be controlled to maximize clinical beneﬁt.1 In addition,
the study reports that the number of patients with AD was
great at baseline (suggesting a causal association between AD
and ACS) and remained high even after statin treatment
(suggesting residual dyslipidemia and consequently higher
cardiovascular disease (CVD) risk than those with frankhypercholesterolemia, which were treated effectively with a
statin).1
Despite the effort to effectively manage all modiﬁable CVD
risk factors, a degree of CVD risk still remains, even after
controlling for arterial hypertension, diabetes mellitus (DM),
smoking, sedentary life style, and attain targets for LDL-C
levels with a statin, according to current guidelines and
standards of care.2 Thus, patients with AD remain at risk for
vascular events, even after effective statin treatment; this is
considered as residual CVD risk (RCVDR).2 RCVDR is attributed
mainly to mixed-combined AD, characterized by elevated
triglyceride (TG), low HDL-C levels, and increased numbers of
small-dense LDL particles.2 AD is common in patients with
type 2 diabetes mellitus (T2DM), obesity or the metabolic
syndrome (MetS), and contributes to both macrovascular and
microvascular RCVDR.2
It has been reported that AD is more often amongst Asian
Indians than in western whites.3 As shown in Fig. 1 frank
hypercholesterolemia with increased LDL-C is more prevalent
in US and Europe, while mixed hyperlipidemia is more
prevalent in Asia and Africa, inducing a greater risk for CVD
than the sole increase of LDL-C. As a result of this the rates of
CVD have accelerated dramatically in South East Asian
Countries, especially in urban areas,3 driven to a signiﬁcant
degree by the metabolic consequences of obesity-dysglyce-
mia-dyslipidemia, such as T2DM and AD, which are common
among South Asians, even in those that are permanently
living in the UK.3
One of the potential mechanisms proposed to explain this
difference is that South Asians have a reduced capacity to
store fatty acids in their less developed primary adipose tissue
compartment (superﬁcial subcutaneous adipose tissue),
which results in earlier utilization of the secondary adipose
tissue compartments (deep subcutaneous adipose tissue and
visceral or intra-abdominal adipose tissue).3 Intra-abdominal
fat accumulation or ectopic fat depositions (non-alcoholic
fatty liver disease, pericardial/epicardial, perivascular, intra-
muscular, peripancreatic, and perirenal) have also adverse
effects on adipokines, glucose metabolism (increase insulin
Fig. 1 – Mixed-AD has a higher prevalence in developing
regions. This is obvious from the differences between the
percent prevalence of frank hypercholesterolemia across 4
different regions according to WHO (http://www.who.int/
gho/ncd/risk_factors/cholesterol_text/en/), in the upper
panel (A), and the percent population-attributable coronary
risk due to dyslipidemia across 4 different regions in the
INTERHEART study (reference 4), in the lower panel (B). The
differences are attributed in part to the high prevalence of
mixed-AD (high TGs and low HDL-C) in Africa and SE Asia,
which has not been included in the WHO evaluation of
frank hypercholesterolemia prevalence.
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in turn are substantial risk factors for the development of
T2DM, AD (mainly due to increased adipocyte transmembrane
ﬂux of fatty acids), or CVD.3 This can explain why the waist to
hip ratio of South Asians is greater than that in whites at
similar body mass index (BMI), and why AD, MetS, and T2DM
are more prevalent in South Asians than in western whites for
the same BMI.3,4 All the above suggest that truncal obesity in
developing regions, such as South East Asia and especially
India, plays a pivotal role in shaping MetS, T2DM, AD, and CVD
rates, because its burden seems to be greater in these areas
(Asia, Africa, and Middle East) than in the developed world (US
and Europe).4
The above conclusions are important because they bring
about the issue of AD and residual dyslipidemia, especially in
India, which seems to have a higher prevalence of these
disorders than those recorded in western countries.1,5 These
conclusions also pave the way for an effective treatment of
residual dyslipidemia, and RCVDR even during the acute phase
of an ACS.1 Up to now, there is only one study addressing this
issue: The study (Acute Coronary Syndrome Israeli SurveysData) included 8982 patients that had an ACS from 2000 to
2010, and received a statin.6 Of these, 8545 (95%) received statin
monotherapy and 437 (5%) received a statin/ﬁbrate combina-
tion.6 The primary endpoint was the 30-day incidence of major
adverse cardiovascular events (MACE) and the secondary the
12 month MACE incidence.6 Overall, there were signiﬁcantly
lower MACEs at 30 days in the statin/ﬁbrate group in
comparison to statin monotherapy group ( p = 0.001).6 Howev-
er, in speciﬁc subgroups, the differences were even greater.
Indeed, in patients with high TGs and in those with low HDL-C
at baseline, the reduction of MACEs was more than 50% and in
patients with T2DM this reduction was almost 80%.6 The 12
month MACE difference was 46% [hazards ratio (HR) = 0.54,
95% conﬁdence interval (CI) 0.32–0.94] in favor of the statin/
ﬁbrate combination.6 These results suggest that, following
conﬁrmation by at least one prospective study, the adminis-
tration of the statin/ﬁbrate combination is useful in patients
with residual dyslipidemia even during the acute phase of an
ACS.6
However, the clinical beneﬁts of the statin/ﬁbrate combi-
nations have been reported in the past and comprise in
keeping CVD morbidity and mortality at very low levels in
patients with mixed hyperlipidemia, both in primary and
secondary CVD prevention.7 Moreover, a subgroup analysis of
The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) Lipid Trial suggests that the statin/ﬁbrate treatment
reduces CVD morbidity and mortality by 31% more than statin
monotherapy in patients with AD.8 Additional post-trial
follow-up of ACCORD patients for a total period of nine years9
revealed ﬁndings similar to the initial ACCORD ﬁndings: the
addition of fenoﬁbrate to simvastatin displayed a 27% further
reduction in CVD events in patients with T2DM and AD
compared to a statin monotherapy (HR = 0.73; 95% CI: 0.56–
0.95) for AD patients, but had no effect on patients with frank
hypercholesterolemia (HR = 0.99; 95% CI: 0.86–1.13; interaction
p = 0.048).9 Finally, a meta-analysis of all major ﬁbrate trials
revealed a 35% (95% CI: 22–46%) reduction in MACE in the
subgroups with AD and a not signiﬁcant one by 6% (95% CI:
5% to 16%) in the subgroups without AD.10
All the above suggest that the statin/ﬁbrate combination is
very useful and substantially reduces RCVDR in patients with
AD but has no effect on patients with frank hypercholesterol-
emia and should not be prescribed in these patients. Overall, if
the signiﬁcant clinical beneﬁt of fenoﬁbrate administration on
microvascular complications of DM (retinopathy, nephropa-
thy, neuropathy, and amputations) is taken into consideration
the entire beneﬁt on life expectancy and quality of life in
patients with T2DM and AD is enormous.
Another very important conclusion of the REMAINS study is
that data from India suggest that the prevalence of both AD
and residual dyslipidemia after statin treatment is higher than
that of western white patients included in studies performed
in US or Europe (Fig. 1),1,5 mainly due to abnormal lipid
deposition.3 Thus, there is a need for local guidelines for the
diagnosis and the treatment of MetS (mainly based on waist to
hip ratio and not on BMI or waist circumference) with speciﬁc
recommendations adjusted to South East Asia criteria.
Moreover, suggestions for treating residual dyslipidemia
should be included in these local guidelines, mainly adopting
the statin/ﬁbrate combinations, because the problem for India
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of the world are required to ﬁll this void of the existing
guidelines.11
Conﬂicts of interest
This editorial was written independently. The authors did not
receive ﬁnancial or professional help with the preparation of
the manuscript. The authors have given talks, attended
conferences, and participated in advisory boards and trials
sponsored by various pharmaceutical companies.
r e f e r e n c e s
1. Salgaonkar VJ, Singh AK, Mundkur SP, Ranjan R. Statin
therapy/lipid lowering therapy among Indian adults with ﬁrst
acute coronary event: The Dyslipidemia Residual and Mixed
Abnormalities IN spite of Statin therapy (REMAINS) Study.
Indian Heart J. 2016;68:646–654.
2. Fruchart JC, Sacks F, Hermans MP, et al. The residual risk
reduction initiative: a call to action to reduce residual
vascular risk in patients with dyslipidemia. Am J Cardiol.
2008;102:1K–34K.
3. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N,
Tchernof A. Why might South Asians be so susceptible to
central obesity and its atherogenic consequences? The
adipose tissue overﬂow hypothesis. Int J Epidemiol.
2007;36:220–225.
4. Guptha S, Gupta R, Deedwania P, et al. Cholesterol lipoproteins
and prevalence of dyslipidemias in urban Asian Indians: a
cross sectional study. Indian Heart J. 2014;66:280–288.
5. Fruchart J-C, Davignon J, Hermans MP, et al. Residual
macrovascular risk in 2013: what have we learned?
Cardiovasc Diabetol. 2014;13:26.6. Tenenbaum A, Medvedofsky D, Fisman EZ, et al.
Cardiovascular events in patients received combined ﬁbrate/
statin treatment versus statin monotherapy: Acute
Coronary Syndrome Israeli Surveys data. PLoS ONE. 2012;7:
e35298.
7. Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin-
ﬁbrate combinations in patients with combined
hyperlipedemia. Atherosclerosis. 2001;155:263–264.
8. The ACCORD Study Group. Effects of combination lipid
therapy in type 2 diabetes mellitus. N Engl J Med.
2010;362:1563–1574.
9. Elam MB, Lovato LC, Ginsberg HN. on behalf of the ACCORD/
ACCORDION Study Group. The effect of combined statin/
ﬁbrate therapy on cardiovascular disease is inﬂuenced by
sex and dyslipidemia: ACCORDION-lipid long-term follow-
up. Circulation. 2015;132:A15997.
10. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy
in type 2 diabetes. N Engl J Med. 2010;363:692–695.
11. Mishra S, Chaturvedi V. Are western guidelines good enough
for Indians? My name is Borat. Indian Heart J. 2015;67:85–89.
Vasilios Gabriel Athyros MD*
Michael Doumas MD
Asterios Karagiannis MD
Aristotelian University, Greece
*Corresponding author.
E-mail address: athyros@med.auth.gr (V.G. Athyros)
Available online 10 March 2016
http://dx.doi.org/10.1016/j.ihj.2016.02.022
0019-4832/
# 2016 Cardiological Society of India. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
